Arno Therapeutics, Inc

Arno Therapeutics, Inc insiders are currently net buyers of ARNI stock, showing bullish sentiment over the past 90 days. Executives have purchased $3.0M while selling $156, resulting in a positive net flow of $3.0M. This buying activity represents 100% of total transaction volume.

Arno Therapeutics, Inc has 12 active insiders who have filed SEC Form 4 transactions in the past 90 days. Steven B. Ruchefsky (Executive) leads with 7 transactions totaling $2.5M. Tomer Kariv (Executive) follows with 27 transactions worth $2.2M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Arno Therapeutics, Inc's current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $3.0M in purchases versus $156 in sales.

The most recent insider transaction occurred on Dec 30, 2016, when Donald Sussman S. (Executive) disposed of 4,285,111 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ARNI insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $3.0M reflects accumulation, with 100% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Arno Therapeutics, Inc. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ARNI, we track all Form 4 filings—currently showing 89 transactions from 12 insiders over 90 days.

A 10b5-1 plan allows Arno Therapeutics, Inc executives to pre-schedule stock sales when they don't possess material non-public information. At ARNI, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ARNI appears discretionary, making insider signals more meaningful.

You can monitor Arno Therapeutics, Inc (ARNI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 12 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Arno Therapeutics, Inc's current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $3.0M in purchases versus $156 in sales over 90 days, resulting in a net flow of $3.0M.

SEC Form 4 filings are mandatory reports that Arno Therapeutics, Inc insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ARNI, the most common type is "P" with 27 occurrences. The most recent Form 4 was filed on Dec 30, 2016 by Donald Sussman S..

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Arno Therapeutics, Inc, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ARNI represents discretionary decisions with more informational value.